From the Research
Pseudoexfoliation (PEX) syndrome affects approximately 2-3% of the general global population over age 60, though prevalence varies significantly by geographic region and ethnicity. The condition becomes more common with advancing age, reaching rates of 10-20% in some populations over age 80. PEX syndrome is particularly prevalent in Scandinavian countries, with rates as high as 20-25% in certain regions of Finland and Iceland, while being less common in North America (1-2%) and relatively rare in African and Asian populations. The condition demonstrates a clear age-dependent increase, rarely appearing before age 50, and shows some familial clustering suggesting genetic factors. Environmental influences like ultraviolet light exposure may also play a role in its development. Some key points to consider about PEX syndrome include:
- The prevalence of PEX syndrome increases with age, with a significant increase after the age of 60 1
- PEX syndrome is more common in women than in men, with a female-to-male ratio of approximately 2:1 2
- The condition is characterized by the production and accumulation of abnormal fibrillar material in ocular tissues, which can lead to elevated intraocular pressure and glaucoma 3
- Approximately 30-50% of PEX patients eventually develop elevated intraocular pressure or glaucoma, making it a significant risk factor for glaucoma development 4 It is essential to note that the prevalence of PEX syndrome can vary significantly depending on the population being studied, and more research is needed to fully understand the condition and its risk factors. However, based on the available evidence, the prevalence of PEX syndrome is a significant concern, particularly in older adults and those with a family history of the condition. In terms of management, topical carbonic anhydrase inhibitors and other glaucoma therapies may be used to reduce intraocular pressure and slow the progression of the disease 5. Overall, early detection and treatment of PEX syndrome are critical to preventing long-term vision loss and improving patient outcomes.